# Progress Note 05 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ella Fitzgerald (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML029-SYN
- Date: 2026-10-26
- Fictional facility: St. Posthumous Health Center
- Fictional author: Odessa Whitlow, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Five-and-a-half-month review: A1c, lipids, walking distance, the revascularization decision, foot and eye follow-up. **S**

## History of present illness

Ms. Fitzgerald returns eleven weeks after her three-month visit. She stepped up to semaglutide 0.5 mg weekly in September; she had mild nausea for the first two weeks, which passed, and she has lost 1.5 kg. Her glucose monitor shows time in range 74% and time below 70 mg/dL 0.6%, with no reading below 54 mg/dL. She finished the supervised exercise program and walks most days; she can now walk about five blocks before calf pain, and only climbing slows her. She has no rest pain and no sores. She has had five right-eye injections and the interval is now eight weeks. The podiatrist saw her in September. She has had no bleeding. Her mammogram in July was normal, and the bone density scan is booked between tours. She feels ready for her winter tour. **S**

| Element | Detail |
|---|---|
| Glucose | Time in range 74%; time below 70 mg/dL 0.6%; none below 54 |
| Semaglutide | 0.5 mg weekly since September; nausea passed |
| Walking | About five blocks; no rest pain |
| Eye treatment | Five injections; now every eight weeks |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Positive | Calf pain only after about five blocks or on hills; no chest pain |
| Gastrointestinal | Negative | Nausea resolved; no vomiting or abdominal pain |
| Eyes | Negative | Right-eye vision clearer |
| Integumentary | Negative | No foot sores |

4 systems reviewed. **S**

## Current medications

- Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals **S**
- Insulin glargine 100 units/mL pen, 24 units under the skin each morning **S**
- Atorvastatin 80 mg oral tablet, one tablet by mouth daily **S**
- Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily **S**
- Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily **S**
- Empagliflozin 10 mg oral tablet, one tablet by mouth each morning **S**
- Glucagon 3 mg nasal powder, one spray into one nostril for a severe low glucose **S**
- Rivaroxaban 2.5 mg oral tablet, one tablet by mouth twice daily with aspirin 81 mg **S**
- Semaglutide 0.5 mg under the skin once weekly **S**
- Ezetimibe 10 mg oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 120/68 mmHg; pulse 60 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 80.6 kg; BMI 29.6 kg/m². All vital signs are synthetic.

Hemoglobin A1c: 7.1% (high); Sodium: 139 mmol/L; Potassium: 4.5 mmol/L; Creatinine: 0.94 mg/dL; eGFR: 65 mL/min/1.73 m²; Total cholesterol: 114 mg/dL; LDL cholesterol: 48 mg/dL; HDL cholesterol: 47 mg/dL (low); Triglycerides: 96 mg/dL; Best-corrected visual acuity, right eye (ETDRS letters): 75 (low); Best-corrected visual acuity, left eye (ETDRS letters): 81. All results are synthetic.

## Change since baseline

- Hemoglobin A1c: 8.6% (high) at baseline, 7.1% (high) at this visit **S**
- Sodium: 139 mmol/L at baseline, 139 mmol/L at this visit **S**
- Potassium: 4.4 mmol/L at baseline, 4.5 mmol/L at this visit **S**
- Creatinine: 0.92 mg/dL at baseline, 0.94 mg/dL at this visit **S**
- eGFR: 67 mL/min/1.73 m² at baseline, 65 mL/min/1.73 m² at this visit **S**
- Total cholesterol: 164 mg/dL at baseline, 114 mg/dL at this visit **S**
- LDL cholesterol: 92 mg/dL at baseline, 48 mg/dL at this visit **S**
- HDL cholesterol: 44 mg/dL (low) at baseline, 47 mg/dL (low) at this visit **S**
- Triglycerides: 140 mg/dL at baseline, 96 mg/dL at this visit **S**
- Best-corrected visual acuity, right eye (ETDRS letters): 64 (low) at baseline, 75 (low) at this visit **S**
- Best-corrected visual acuity, left eye (ETDRS letters): 81 at baseline, 81 at this visit **S**

## Immunizations given today

- Influenza vaccine, high-dose, 2026-2027 season **S**
- Recombinant zoster vaccine, dose 1 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 80.6 kg, BMI 29.6; blood pressure 120/68, pulse 60 |
| Feet | Skin intact; minimal callus; hammer toes; no ulcer; monofilament felt at all sites; right foot pulses absent, left faint; feet warm |
| Eyes | Best-corrected acuity 75 letters right and 81 letters left |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Type 2 diabetes with peripheral artery disease** (E11.51). A1c 7.1%, at her goal below 7.5%, with no level 2 or 3 lows. After supervised exercise she walks about five blocks, and claudication no longer limits her daily life or her performing, so revascularization is not needed now; Dr. Okafor-Lane agrees by message. Creatinine 0.94 mg/dL, eGFR 65, potassium 4.5 mmol/L. **S**
   - Continue metformin, empagliflozin, semaglutide 0.5 mg weekly, and glargine 24 units.
   - Walk at least three times a week for life.
   - Vascular review with ankle-brachial index and duplex next month, as planned.
   - Podiatry every three months; foot check at every visit.
2. **Coronary artery disease after bypass surgery** (I25.10). LDL 48 mg/dL, at goal, on atorvastatin 80 mg and ezetimibe; total cholesterol 114, HDL 47, triglycerides 96 mg/dL. **S**
   - Continue atorvastatin, ezetimibe, aspirin, rivaroxaban, and metoprolol.
   - Lipid panel yearly.
3. **Immunizations**. Influenza and recombinant zoster vaccines due this autumn, as planned at the wellness visit. **S**
   - High-dose influenza vaccine and recombinant zoster vaccine dose 1 given today; zoster dose 2 in two to six months; COVID-19 and RSV vaccines at her pharmacy before the winter tour.
4. **Diabetic macular edema, right eye** (E11.3311). Acuity 75 letters, from 64 at intake; no worsening of retinopathy reported by the retina clinic since semaglutide began. **S**
   - Continue retina-clinic treatment every eight weeks; left eye examined at each visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Hemoglobin A1c | Every three months when not at goal or after a change; every six months at goal | Completed today | 7.1%, at goal; every six months from now |
| Medication safety | Continuous glucose monitor review: time in range and time below range | Every visit | Completed today | Time in range 74%; time below 70 mg/dL 0.6% |
| Medication safety | Hypoglycemia events, show-day plan, and glucagon | Every visit | Completed today | No level 2 or 3 lows since intake |
| Medication safety | Empagliflozin safety: genital infection, volume, and sick-day rules | At the start and every visit | Completed today | No side effects |
| Laboratory | Creatinine, eGFR, and potassium | Within three months of starting an SGLT2 inhibitor, then every six to twelve months; potassium on SGLT2 inhibitor and rivaroxaban review | Completed today | Creatinine 0.94 mg/dL, eGFR 65, potassium 4.5, sodium 139 mmol/L |
| Laboratory | Urine albumin-creatinine ratio | Yearly | Up to date | 18 mg/g at intake; repeat at the next yearly check |
| Laboratory | Lipid panel | 4 to 12 weeks after a statin or other lipid-lowering change, then yearly | Completed today | LDL 48 mg/dL eleven weeks after ezetimibe was added, at goal |
| Examination | Foot inspection, protective sensation, and pulses | Every visit with peripheral artery disease and foot deformity (IWGDF risk 2); podiatry every three to six months | Completed today | No ulcer; podiatry in September; next in December |
| Imaging | Ankle-brachial and toe-brachial indices | At diagnosis; repeat with arterial duplex six months after the consultation or with any change in symptoms | Due | With arterial duplex at the vascular review next month, six months after the consultation |
| Examination | Walking distance and claudication symptoms | Every visit | Completed today | About five blocks; claudication no longer limits her |
| Self-management | Supervised exercise therapy | Three times a week for twelve weeks | Completed today | Program completed; walking most days |
| Imaging | Retinal examination and visual acuity | With each retina-clinic treatment while macular edema is treated; at least yearly in both eyes | Completed today | Acuity 75 letters right and 81 left; five injections |
| Examination | Blood pressure | Every visit | Completed today | 120/68 mmHg |
| Examination | Weight and BMI | Every visit | Completed today | 80.6 kg, down 3.4 kg since intake |
| Medication safety | Bleeding on rivaroxaban and aspirin | At the start and every visit | Completed today | No bleeding |
| Medication safety | Semaglutide tolerance: nausea, appetite, and dose step | At the start and each dose step | Completed today | 0.5 mg weekly; nausea passed |
| Self-management | Access and equity: tour-date scheduling, video visits, large print, drug costs | Every visit | Completed today | Video visit planned during the winter tour; prescriptions synchronized for travel |

## Goal progress

- No glucose below 70 mg/dL on most days and no level 2 or 3 low (below 54 mg/dL or needing help) through six months. Outcome by 2026-10-26: No level 2 or 3 lows since intake; time below 70 mg/dL under 1%. **S**
- A1c below 7.5% by six months. Outcome by 2026-10-26: A1c 7.1%. **S**
- LDL cholesterol below 55 mg/dL by six months. Outcome by 2026-10-26: LDL 48 mg/dL on atorvastatin 80 mg and ezetimibe. **S**
- Walk at least four blocks without stopping by six months. Outcome by 2026-10-26: Walks about five blocks before calf pain. **S**
- No foot ulcer, and protective footwear on and off stage, through six months. Outcome by 2026-10-26: No ulcer; low-heeled custom stage shoes and protective daily shoes. **S**

## Guideline basis

- Standards of Care in Diabetes—2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update) (2023), International Working Group on the Diabetic Foot (Diabetes Metab Res Rev 2024)
- 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024), American College of Cardiology and American Heart Association (Circulation 2024)
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology (Circulation)
- CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026), Aether Forge
- Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial (2025), The Lancet (Bonaca MP, et al.)

## Follow-up

- Vascular review with ankle-brachial index and duplex next month. Podiatry in December. Retina clinic every eight weeks. Video visit during the winter tour; in-person review in three months with A1c. **S**

